This novel monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – represents considerable promise for the treatment of acute hemolytic disease (TRALI). Engineered by the company, Pritoxaximab works by https://www.targetmol.com/compound/pritoxaximab